Literature DB >> 10340283

Endometrial cancer after combined hormone replacement therapy.

D M Gruber1, G Wagner, C Kurz, M O Sator, J C Huber.   

Abstract

OBJECTIVE: It has been suggested that exposure to relatively high levels of unopposed estrogen is a risk factor for endometrial cancer. Combined therapy of estrogen with cyclic progestagen was therefore highly recommended for menopausal women with an intact uterus.
METHODS: The cases of two postmenopausal women who developed endometrial cancer after taking continuous sequential HRT for 15 months are reported. Both were without bleeding for more than 2 years and presented with a normal vaginal ultrasound. They had severe menopausal symptoms and asked for HRT.
RESULTS: After 15 months irregular bleeding occurred and a hysterectomy was performed. The pathohistological finding in both cases was endometrial cancer. As we measured the serum estradiol levels 4 h after tablet ingestion supraphysiologic values ranging between 418 and 442 pg/ml were found.
CONCLUSION: Our report strengthens the evidence that supraphysiologic estradiol levels despite combination with cyclic progestagen therapy, increase the risk of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340283     DOI: 10.1016/s0378-5122(99)00007-9

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  2 in total

Review 1.  Carcinoma of the endometrium.

Authors:  B M Southcott
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Social and Cultural Factors Affecting Complementary and Alternative Medicine (CAM) Use during Menopause in Sydney and Bologna.

Authors:  Corinne van der Sluijs; Flavia L Lombardo; Grazia Lesi; Alan Bensoussan; Francesco Cardini
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-26       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.